Stock MBRX MOLECULIN BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Real-time Estimate Cboe BZX
Other stock markets
 11:16:36 2024-04-29 EDT 		5-day change 1st Jan Change
4.895 USD +5.72% Intraday chart for Moleculin Biotech, Inc. +14.87% -61.64%
04-18 Sector Update: Health Care Stocks Ease in Afternoon Trading MT
04-18 Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU MT

Evolution of the average Target Price on Moleculin Biotech, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d1670b716f061f7d47a6.M9eNZyaZNT2Bsq_-6_Tm9ze4IV1XokSz3YGM3i4SCGE.RYL7CEHLXErQ4czGpoTVnX_5GG5m6QfDuMv8iGhAXSJlv8xTZfBPDPbj_g~94982c6e3d07ce2a3448e1b6cab23d73

Analyst Recommendations on Moleculin Biotech, Inc.

Maxim Adjusts Price Target on Moleculin Biotech to $20 From $45, Maintains Buy Rating MT
HC Wainwright Initiates Moleculin Biotech With Buy Rating, Price Target is $3 MT
Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months CI
Roth Capital Adjusts Moleculin Biotech's Price Target to $16 From $29, Reiterates Buy Rating MT
MOLECULIN BIOTECH : Oppenheimer Adjusts Moleculin Biotech's Price Target to $18 From Post-Split Adjusted $12, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
4.63 USD
Average target price
35 USD
Spread / Average Target
+655.94%
High Price Target
45 USD
Spread / Highest target
+871.92%
Low Price Target
20 USD
Spread / Lowest Target
+331.97%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Moleculin Biotech, Inc.

Maxim
HC Wainwright
Roth Capital Partners
Oppenheimer

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MBRX Stock
  4. Consensus Moleculin Biotech, Inc.